Therapeutics News and Research

RSS

VistaGen Therapeutics announces new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells

VistaGen Therapeutics, Inc., a biotechnology company using leading-edge embryonic stem cell (ES Cell) technologies for predictive toxicology and drug discovery, has announced new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells. VistaGen has exclusive rights for commercial use in its ES Cell-based tools platform for drug discovery and development.

16 Jun 2008

Compugen announces discovery of novel drug targets for cancer antibody therapeutics

Compugen Ltd. announced today the discovery of more than ten novel targets of antibody therapy for various types of solid and hematopoietic cancer.

11 Jun 2008

Without increased funding, California's dominance and public health are threatened, according to new report

The California Healthcare Institute (CHI) and PricewaterhouseCoopers (PwC) today released a report, "The National Institutes of Health: Fueling Healthcare Innovation in California," urging legislators to support increased funding for the National Institutes of Health (NIH) - the backbone of the biomedical industry in California, which employs more than 267,000 people in high wage jobs.

11 Jun 2008

Boehringer, Gilead freeze antiretroviral prices for some U.S. agencies

Pharmaceutical companies Boehringer Ingelheim and Gilead Sciences are freezing the prices of their antiretroviral drugs for select agencies in the U.S., the AIDS Healthcare Foundation announced on Tuesday, Bloomberg reports.

8 Jun 2008

Boehringer Ingelheim, Gilead to freeze AIDS drug price

AIDS Healthcare Foundation (AHF) today applauded decisions by Boehringer Ingelheim (BI) and Gilead Sciences, Inc. to freeze prices on antiretroviral medications purchased by government agencies.

3 Jun 2008

CSL Behring study shows extended half-life recombinant VIIa leads to longer biologic activity

CSL Behring today presented results of a pre-clinical study that not only demonstrates the feasibility of genetically fusing factor VIIa to human albumin, but that this therapeutic protein with a prolonged half-life can lead to a longer biologic effect.

3 Jun 2008

Paclitaxel Poliglumex/Capecitabine regimen well tolerated and active in metastatic breast cancer

At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (Opaxio, CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC).

3 Jun 2008

Arana and Greenovation in anti-cancer co-development deal

Arana Therapeutics Limited and Germany-based greenovation Biotech GmbH have entered into a collaborative agreement to develop next generation anti-cancer antibodies.

2 Jun 2008

Celldex Therapeutics vaccine may double survival in patients with deadly brain tumors

A vaccine aimed at inducing immunity to the most common and deadly type of brain tumor may stave off recurrence and more than double survival in patients, according to a new study led by researchers in Duke's Preston Robert Tisch Brain Tumor Center.

2 Jun 2008

U.S. Patent Office confirms second of four Viread patents

Gilead Sciences, Inc. has announced that the U.S. Patent & Trademark Office (PTO) has completed the second of four reexamination proceedings and has confirmed the patentability of U.S. Patent No. 5,922,695, which covers the composition of matter for Viread (tenofovir disoproxil fumarate). On May 20, Gilead announced that the U.S. PTO confirmed the patentability of U.S. Patent No. 6,043,230.

2 Jun 2008

New cancer stem cell identified behind metastatic tumors

The molecular profile of cancer stem cells that initiate metastatic colon tumors is significantly different from those responsible for primary tumors, according to new research from a team at Weill Cornell Medical College.

28 May 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008

Boost for cancer research in Leicestershire

A new approach to pain relief, investigation of a gene that triggers colorectal cancer and the prevention, early diagnosis and treatment of ovarian cancer are three research projects at the University of Leicester, which are to benefit from funding from the Leicestershire and Rutland charity Hope Against Cancer.

21 May 2008

Oncolytics Biotech announces issuance of 27th U.S. patent

Oncolytics Biotech Inc. today announced that it has been granted U.S. Patent 7,374,752 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders."

20 May 2008

Mapping of prostate cancer genes opens the door to new treatments

Genetic changes during the initiation and progression of prostate cancer have eluded scientists to date. Now for the first time researchers have identified a specific gene expression profile of prostate cancer stem cells, with important implications for future treatments.

19 May 2008

Erection problems may signal serious heart disease

Erectile dysfunction is always a matter of the heart, but new research shows that more than romance is at stake. Two new studies of men with type 2 diabetes found that erectile dysfunction (ED) was a powerful early warning sign for serious heart disease, including heart attack and death.

19 May 2008

U.S. patent office grants re-examination of RNA splicing microarray patent on behalf of Jivan

Jivan Biologics, Inc. announced today that the United States Patent and Trademark Office has ordered the re-examination of U.S. Patent No. 6,881,571. The serial number for the reexamination is 90/009,017.

19 May 2008

Biopure Corporation wins European patent challenge

Biopure Corporation announced today that it has successfully defended a challenge at the European Patent Office (EPO) to its European Patent entitled, "A Method for Chromatographic Removal of Prions."

19 May 2008

Cancer Research UK and AstraZeneca announce innovative deal for promising anti-cancer compound

Cancer Research UK and Cancer Research Technology (CRT) - the charity's development and commercialisation arm - today announced an innovative new arrangement to progress into clinical development a potential anti-cancer compound from AstraZeneca.

19 May 2008

Personalized therapy for asthma and chronic obstructive pulmonary disease could soon be here

Researchers at Washington University School of Medicine in St. Louis have defined a new type of immune response that is activated in patients with severe asthma and COPD (chronic obstructive pulmonary disease). Their discovery could dramatically improve diagnosis and treatment of patients with chronic inflammatory lung disease.

19 May 2008

Therapeutics News and Research

VistaGen Therapeutics announces new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells

Compugen announces discovery of novel drug targets for cancer antibody therapeutics

Without increased funding, California's dominance and public health are threatened, according to new report

Boehringer, Gilead freeze antiretroviral prices for some U.S. agencies

Boehringer Ingelheim, Gilead to freeze AIDS drug price

CSL Behring study shows extended half-life recombinant VIIa leads to longer biologic activity

Paclitaxel Poliglumex/Capecitabine regimen well tolerated and active in metastatic breast cancer

Arana and Greenovation in anti-cancer co-development deal

Celldex Therapeutics vaccine may double survival in patients with deadly brain tumors

U.S. Patent Office confirms second of four Viread patents

New cancer stem cell identified behind metastatic tumors

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

Boost for cancer research in Leicestershire

Oncolytics Biotech announces issuance of 27th U.S. patent

Mapping of prostate cancer genes opens the door to new treatments

Erection problems may signal serious heart disease

U.S. patent office grants re-examination of RNA splicing microarray patent on behalf of Jivan

Biopure Corporation wins European patent challenge

Cancer Research UK and AstraZeneca announce innovative deal for promising anti-cancer compound

Personalized therapy for asthma and chronic obstructive pulmonary disease could soon be here

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News